This report provides comprehensive information on the therapeutic development for Posterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Posterior Uveitis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Posterior Uveitis Overview
- Therapeutics Development
- Pipeline Products for Posterior Uveitis - Overview
- Pipeline Products for Posterior Uveitis - Comparative Analysis
- Posterior Uveitis - Therapeutics under Development by Companies
- Posterior Uveitis - Therapeutics under Investigation by Universities/Institutes
- Posterior Uveitis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Posterior Uveitis - Products under Development by Companies
- Posterior Uveitis - Products under Investigation by Universities/Institutes
- Posterior Uveitis - Companies Involved in Therapeutics Development
- Aciont Inc.
- Neuroptis Biotech
- Oculis ehf
- pSivida Corp.
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- ThromboGenics NV
- Virogenomics BioDevelopment, Inc.
For more information visit http://www.researchandmarkets.com/research/4973lw/posterior_uveitis